BR112023024595A2 - Receptores de células t direcionando mutações ras e usos dos mesmos - Google Patents
Receptores de células t direcionando mutações ras e usos dos mesmosInfo
- Publication number
- BR112023024595A2 BR112023024595A2 BR112023024595A BR112023024595A BR112023024595A2 BR 112023024595 A2 BR112023024595 A2 BR 112023024595A2 BR 112023024595 A BR112023024595 A BR 112023024595A BR 112023024595 A BR112023024595 A BR 112023024595A BR 112023024595 A2 BR112023024595 A2 BR 112023024595A2
- Authority
- BR
- Brazil
- Prior art keywords
- cell receptors
- ras mutations
- receptors targeting
- targeting ras
- ras
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/32—T-cell receptors [TCR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4244—Enzymes
- A61K40/4253—GTPases, e.g. Ras or Rho
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/82—Translation products from oncogenes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5156—Animal cells expressing foreign proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163192783P | 2021-05-25 | 2021-05-25 | |
| PCT/US2022/030814 WO2022251283A1 (en) | 2021-05-25 | 2022-05-25 | T cell receptors targeting ras mutations and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112023024595A2 true BR112023024595A2 (pt) | 2024-02-15 |
Family
ID=84230235
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112023024595A BR112023024595A2 (pt) | 2021-05-25 | 2022-05-25 | Receptores de células t direcionando mutações ras e usos dos mesmos |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240091361A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4347639A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024520427A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240013750A (cg-RX-API-DMAC7.html) |
| CN (1) | CN117545766A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022283277A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112023024595A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3219923A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL308755A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2023014073A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022251283A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4573114A4 (en) * | 2022-08-19 | 2026-07-29 | Memorial Sloan Kettering Cancer Center | T-LYMPHOCYTE RECEPTORS TARGETTING RAS MUTATIONS AND ASSOCIATED USES |
| US20260232734A1 (en) * | 2023-02-27 | 2026-08-13 | Adaptive Biotechnologies Corporation | Therapeutic T-Cell Receptors Targeting KRAS G12D |
| CN118812698A (zh) * | 2023-04-19 | 2024-10-22 | 香雪生命科学技术(广东)有限公司 | 一种识别kras突变的高亲和力t细胞受体及其应用 |
| KR20260024373A (ko) * | 2023-05-05 | 2026-02-20 | 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 | 다중-수용체 자연 살해 세포 |
| WO2025054164A1 (en) * | 2023-09-05 | 2025-03-13 | Bluesphere Bio, Inc. | T cell receptors targeting an npm1 neoantigen |
| AU2024408100A1 (en) * | 2023-12-22 | 2026-08-06 | Abata Therapeutics, Inc. | Cell therapies for type 1 diabetes |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2635335T3 (es) * | 2010-09-20 | 2017-10-03 | Biontech Cell & Gene Therapies Gmbh | Receptores de células T específicos de antígeno y epítopos de células T |
| MX2020001879A (es) * | 2017-08-18 | 2020-07-29 | Gritstone Oncology Inc | Proteínas de fijación al antígeno que se dirigen a antígenos compartidos. |
| MX2020005765A (es) * | 2017-12-04 | 2020-09-25 | Us Health | Receptores de celulas t restringidos a antigeno leucocitario humano (hla) clase i contra sarcoma de rata (ras) mutado. |
| US20200129555A1 (en) * | 2018-10-24 | 2020-04-30 | The United States Of America,As Represented By The Secretary,Department Of Health And Human Services | Hla-a3-restricted t cell receptors against mutated ras |
| CA3127673A1 (en) * | 2019-01-25 | 2020-07-30 | The Trustees Of The University Of Pennsylvania | Compositions and methods for targeting mutant ras |
| GB2613715B (en) * | 2019-02-20 | 2023-12-06 | Fred Hutchinson Cancer Center | Binding proteins specific for RAS neoantigens and uses thereof |
-
2022
- 2022-05-25 KR KR1020237041629A patent/KR20240013750A/ko active Pending
- 2022-05-25 AU AU2022283277A patent/AU2022283277A1/en active Pending
- 2022-05-25 BR BR112023024595A patent/BR112023024595A2/pt not_active Application Discontinuation
- 2022-05-25 CN CN202280045185.0A patent/CN117545766A/zh active Pending
- 2022-05-25 IL IL308755A patent/IL308755A/en unknown
- 2022-05-25 WO PCT/US2022/030814 patent/WO2022251283A1/en not_active Ceased
- 2022-05-25 MX MX2023014073A patent/MX2023014073A/es unknown
- 2022-05-25 CA CA3219923A patent/CA3219923A1/en active Pending
- 2022-05-25 EP EP22812027.5A patent/EP4347639A4/en active Pending
- 2022-05-25 JP JP2023572797A patent/JP2024520427A/ja active Pending
-
2023
- 2023-11-22 US US18/517,835 patent/US20240091361A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4347639A1 (en) | 2024-04-10 |
| US20240091361A1 (en) | 2024-03-21 |
| KR20240013750A (ko) | 2024-01-30 |
| WO2022251283A1 (en) | 2022-12-01 |
| AU2022283277A9 (en) | 2024-01-04 |
| CA3219923A1 (en) | 2022-12-01 |
| CN117545766A (zh) | 2024-02-09 |
| JP2024520427A (ja) | 2024-05-24 |
| AU2022283277A1 (en) | 2023-12-14 |
| EP4347639A4 (en) | 2025-08-06 |
| IL308755A (en) | 2024-01-01 |
| MX2023014073A (es) | 2024-02-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023014073A (es) | Receptores de linfocitos t que se dirigen a mutaciones de ras y usos de los mismos. | |
| BR112023022297A2 (pt) | Receptores quiméricos que alvejam adgre2 e/ou clec12a e usos dos mesmos | |
| ECSP22051701A (es) | Anticuerpos anti-cd73 y usos de estos | |
| Voss et al. | Fatty acid synthase contributes to restimulation-induced cell death of human CD4 T cells | |
| Rao et al. | AMPK-dependent and independent effects of AICAR and compound C on T-cell responses | |
| Haskó et al. | Adenosine: a potential mediator of immunosuppression in multiple organ failure | |
| MX2021001009A (es) | Composiciones y métodos para la reprogramación de tcr mediante el uso de proteínas de fusión específicas de la diana. | |
| BR112019007100A2 (pt) | composições e métodos para reprogramação de receptores de célula t com o uso de proteínas de fusão | |
| BR112023002150A2 (pt) | Anticorpos direcionando egfr e uso dos mesmos | |
| BR112022003826A2 (pt) | Métodos para gerar e isolar neurônios de dopamina do mesencéfalo, população celular, composição e kit | |
| Zhdanov et al. | Inhibition of telomerase activity and induction of apoptosis by Rhodospirillum rubrum l‐asparaginase in cancer Jurkat cell line and normal human CD4+ T lymphocytes | |
| Kaufmann | The human intra-S checkpoint response to UVC-induced DNA damage | |
| MX2023013001A (es) | Compuestos para inhibir o degradar itk, composiciones que comprenden los mismos, metodos para su elaboracion y metodos para su uso. | |
| MX2023013723A (es) | Polipeptidos de il-21 y construcciones dirigidas. | |
| CL2025001720A1 (es) | Productos terapéuticos dirigidos al receptor de somatostatina subtipo 2 (sst2r) y usos de la misma | |
| Lee et al. | Marine-derived secondary metabolite, Griseusrazin A, suppresses inflammation through heme oxygenase-1 induction in activated RAW264. 7 macrophages | |
| WO2022010914A3 (en) | Brk peptides and methods of use | |
| Adams et al. | Proteomic responses of sea urchin embryos to stressful ultraviolet radiation | |
| Seo et al. | Rosa gallica and its active compound, cyanidin‐3, 5‐O‐diglucoside, improve skin hydration via the GLK signaling pathway | |
| Kavitha et al. | Differential regulation of MRN (Mre11–Rad50–Nbs1) complex subunits and telomerase activity in cancer cells | |
| Saitoh et al. | Antitumor activity of Hypsizigus marmoreus. II. Preventive effect against lung metastasis of Lewis lung carcinoma | |
| Figueroa-Hernández et al. | Plant products with anti-cancer properties employed in the treatment of bowel cancer: literature review 1985 and 2004. | |
| BR112022024071A2 (pt) | Compostos moduladores de tlr2, composições farmacêuticas e usos dos mesmos | |
| Meng et al. | Relationship between micronucleus formation and oxidative stress in human vascular endothelial cells under low dose rate irradiation | |
| EA202190370A1 (ru) | Инъекционные системы, инъекционные инструменты и связанные с ними способы |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
| B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |